Communication in Drug Development: “Translating” Scientific Discovery
نویسندگان
چکیده
منابع مشابه
Communication in Drug Development: “Translating” Scientific Discovery
The discovery and development of new medicines that promote human health and potentially extend natural life remains a remarkably challenging endeavor. In this Commentary, we identify key elements of communication required to successfully translate promising biological findings to novel approved drug therapies and discuss the attendant challenges and opportunities.
متن کاملEthnobotany, Ethnopharmacology and Drug Discovery
This manuscript is a review of a number of ethnobotany and ethnopharmacology texts and papers in order to arrive at current understanding and scope of ethnobotany and ethnopharmacology. It includes either a brief definition of both fields and presenting some examples on them. Also it has a glimpse on the geographical coverage of research works throughout the world, important issue of prope...
متن کاملScientific Issues in Botanical Drug Product Development
In recent years, as more and more innovative drug products are going off patents, the search for new medicines such as botanical drug products that can treat critical and/or life-threatening diseases has become the center of attention of many pharmaceutical companies and research organizations such as the United States National Institutes of Health (NIH). A botanical drug product is often recog...
متن کاملDrug discovery and development: India
Implementation period CDRI was established in 1951 and has pursued various broad-based and long-term drug development projects over the ensuing five decades.This approach has led to the development of a pipeline of products from natural resources, including the commercialization of at least five lead compounds or products: gugulipid (hypolipidaemic), Bacopa monniera standardized fraction (memor...
متن کاملDrug development: portals of discovery.
A British humorist said, "There is much to be said for failure. It is much more interesting than success." This CCR Focus section is aimed at identifying lessons to be learned from difficulties encountered in recent years during development of anticancer agents. Clearly, we have not found a silver bullet tyrosine kinase inhibitor against solid tumors comparable with imatinib in chronic myelogen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cell
سال: 2016
ISSN: 0092-8674
DOI: 10.1016/j.cell.2016.02.050